
Sharon O Toole

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6826580/publications.pdf Version: 2024-02-01



SHADON O TOOLE

#	Article	IF	CITATIONS
1	Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell?. Molecular Cancer, 2021, 20, 59.	19.2	70
2	The MTS assay as an indicator of chemosensitivity/resistance in malignant gynaecological tumours. Cancer Detection and Prevention, 2003, 27, 47-54.	2.1	49
3	FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer. British Journal of Cancer, 2020, 122, 361-371.	6.4	38
4	Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer. BMC Cancer, 2015, 15, 547.	2.6	37
5	Influenza A virus causes maternal and fetal pathology via innate and adaptive vascular inflammation in mice. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24964-24973.	7.1	34
6	<i>BRCA1</i> Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. Journal of the National Cancer Institute, 2020, 112, 1190-1203.	6.3	32
7	Non-invasive and non-destructive measurements of confluence in cultured adherent cell lines. MethodsX, 2015, 2, 8-13.	1.6	30
8	HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells. Cancers, 2020, 12, 3734.	3.7	22
9	Oestrogen regulated gene expression in normal and malignant endometrial tissue. Maturitas, 2005, 51, 187-198.	2.4	18
10	Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells. Experimental Cell Research, 2015, 336, 1-14.	2.6	16
11	GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions. Cancers, 2021, 13, 493.	3.7	14
12	Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview. International Journal of Molecular Sciences, 2021, 22, 3822.	4.1	12
13	Analysis of DNA in Endometrial Cancer Cells Treated with Phyto-Estrogenic Compounds using Comparative Genomic Hybridisation Microarrays. Planta Medica, 2005, 71, 435-439.	1.3	11
14	Circulating tumour cell enumeration does not correlate with Miller–Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2020, 181, 571-580.	2.5	9
15	An Overview of the Role of Long Non-Coding RNAs in Human Choriocarcinoma. International Journal of Molecular Sciences, 2021, 22, 6506.	4.1	8
16	LncRNA MORT (ZNF667-AS1) in Cancer—Is There a Possible Role in Gynecological Malignancies?. International Journal of Molecular Sciences, 2021, 22, 7829.	4.1	7
17	The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer. PLoS ONE, 2020, 15, e0243715.	2.5	7
18	Epithelioid Trophoblastic Tumour: A Case with Genetic Linkage to a Child Born over Seventeen Years Prior, Successfully Treated with Surgery and Pembrolizumab. Current Oncology, 2021, 28, 5346-5355.	2.2	6

SHARON O TOOLE

#	Article	IF	CITATIONS
19	MyD88 is an essential component of retinoic acid-induced differentiation in human pluripotent embryonal carcinoma cells. Cell Death and Differentiation, 2017, 24, 1975-1986.	11.2	5
20	Prevalence and concordance of oral HPV infections with cervical HPV infections in women referred to colposcopy with abnormal cytology. Journal of Oral Pathology and Medicine, 2021, 50, 692-699.	2.7	5
21	Human papillomavirus detection and genotyping, by HC2, full-spectrum HPV and molecular beacon real-time HPV assay in an Irish colposcopy clinic. Journal of Virological Methods, 2014, 201, 93-100.	2.1	4
22	The value of human epididymis 4, <scp>D</scp> â€dimer, and fibrinogen compared with CAÂ125 alone in triaging women presenting with pelvic masses: a retrospective cohort study. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 1239-1247.	2.8	2
23	The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer. , 2020, 15, e0243715.		0
24	The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer. , 2020, 15, e0243715.		0
25	The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer. , 2020, 15, e0243715.		0
26	The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer. , 2020, 15, e0243715.		0